Abstract
Mucin-type O-glycans are upregulated and aberrantly glycosylated in many carcinomas. O-glycan Core 1 (Galβ1-3GalNAcα-O-), also called Thomsen-Friedenreich disaccharide, is a cryptic structure overexpressed in cancer cells through modification of its glycosyltransferase profile. This molecule is a useful model for study of carbohydrate immunogenicity as well as a candidate for active specific immunotherapy of cancer patients. Several strategies are discussed for enhancing immune response to a particular region of carbohydrate: carbohydrate-protein conjugation, linkers, synthetic clustered sugars, chemical modifications, peptide / protein mimetics, and molecular rotation.
Keywords: thomsen-friedenreich disaccharide, mucin-type o-glycans, o-glycan core 1, glycosyltransferase, immunogenicity, carbohydrate-protein conjugation,, synthetic clustered sugars, peptide/protein mimetics, molecular rotation
Current Cancer Drug Targets
Title: Thomsen-Friedenreich Disaccharide Immunogenicity
Volume: 3 Issue: 6
Author(s): Fernando J. Irazoqui and Gustavo A. Nores
Affiliation:
Keywords: thomsen-friedenreich disaccharide, mucin-type o-glycans, o-glycan core 1, glycosyltransferase, immunogenicity, carbohydrate-protein conjugation,, synthetic clustered sugars, peptide/protein mimetics, molecular rotation
Abstract: Mucin-type O-glycans are upregulated and aberrantly glycosylated in many carcinomas. O-glycan Core 1 (Galβ1-3GalNAcα-O-), also called Thomsen-Friedenreich disaccharide, is a cryptic structure overexpressed in cancer cells through modification of its glycosyltransferase profile. This molecule is a useful model for study of carbohydrate immunogenicity as well as a candidate for active specific immunotherapy of cancer patients. Several strategies are discussed for enhancing immune response to a particular region of carbohydrate: carbohydrate-protein conjugation, linkers, synthetic clustered sugars, chemical modifications, peptide / protein mimetics, and molecular rotation.
Export Options
About this article
Cite this article as:
Irazoqui J. Fernando and Nores A. Gustavo, Thomsen-Friedenreich Disaccharide Immunogenicity, Current Cancer Drug Targets 2003; 3 (6) . https://dx.doi.org/10.2174/1568009033481714
DOI https://dx.doi.org/10.2174/1568009033481714 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
Current Pharmaceutical Design Design, Synthesis and in vitro Cytotoxicity Evaluation of New 3',4'-bis (3,4,5-trisubstituted)-4'H-spiro[indene-2,5'-isoxazol]-1(3H)-one Derivatives as Promising Anticancer Agents
Letters in Drug Design & Discovery Fertility Preservation in Women After the Cancer
Current Pharmaceutical Design Meet Our Associate Editorial Board Member
Current Nanomedicine Development and In Vitro Proof-of-Concept of Interstitially Targeted Zinc- Phthalocyanine Liposomes for Photodynamic Therapy
Current Medicinal Chemistry Syntheses and Antitumor Activities of Potent Inhibitors of Ribonucleotide Reductase: 3-Amino-4-Methylpyridine-2-Carboxaldehyde-Thiosemicarbazone (3-Amp), 3-Amino-Pyridine-2-Carboxaldehyde-Thiosemicarbazone (3-Ap) and its Water-Soluble Prodrugs
Current Medicinal Chemistry A Single Pill to Treat Postmenopausal Hypertension? Not Yet
Current Topics in Medicinal Chemistry Monoclonal Antibodies in Solid Tumours
Current Clinical Pharmacology Effects of Olive Oil on TNF-α and IL-6 in Humans: Implication in Obesity and Frailty
Endocrine, Metabolic & Immune Disorders - Drug Targets Disposition of Pharmacologically Active Dietary Isoflavones in Biological Systems
Current Drug Metabolism Anticancer Properties of Essential Oils: An Overview
Current Cancer Drug Targets Patent Review on Nanotechnology in Ocular Drug Delivery
Recent Patents on Nanomedicine The Influences of Aconitine, an Active/Toxic Alkaloid from Aconitum, on the Oral Pharmacokinetics of CYP3A Probe Drug Buspirone in Rats
Drug Metabolism Letters Design, Synthesis and Anticancer Activity Against the MCF-7 Cell Line of Benzo-Fused 1,4-Dihetero Seven- and Six-Membered Tethered Pyrimidines and Purines
Current Medicinal Chemistry State of the Art of Biochemical Markers in Metastatic Bone Disease and the Role of Bisphosphonates as Therapeutic Agents
Current Pharmaceutical Analysis Radionuclide Imaging in Drug Development
Current Pharmaceutical Design Effects of Epirubicin and Cisplatin Against 4T1 Breast Cancer Cells are Enhanced by Myrtucommulone-A
Anti-Cancer Agents in Medicinal Chemistry Extracellular Tropomyosin: A Novel Common Pathway Target for Anti- Angiogenic Therapy
Current Cancer Drug Targets Treatment of Central Nervous System Involvement Associated with Primary Sjogrens Syndrome
Current Pharmaceutical Design Multidrug Transporters as Drug Targets
Current Drug Targets